Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Belinostat |
Synonyms | |
Therapy Description |
Beleodaq (belinostat) is an HDAC inhibitor, which promotes tumor cell apoptosis, potentially leading to decreased tumor growth (PMID: 12939461, PMID: 16928830, PMID: 17935615). Beleodaq (belinostat) is FDA approved for patients with relapsed or refractory peripheral T-cell lymphoma (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Belinostat | Beleodaq | PDX101|NSC726630|PX-105684 | HDAC Inhibitor 45 | Beleodaq (belinostat) is an HDAC inhibitor, which promotes tumor cell apoptosis, potentially leading to decreased tumor growth (PMID: 12939461, PMID: 16928830, PMID: 17935615). Beleodaq (belinostat) is FDA approved for patients with relapsed or refractory peripheral T-cell lymphoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FBXW7 inact mut | Advanced Solid Tumor | sensitive | Belinostat | Preclinical | Actionable | In a preclinical study, Beleodaq (belinostat) inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). | 23274910 |
FBXW7 inact mut | hematologic cancer | sensitive | Belinostat | Preclinical | Actionable | In a preclinical study, Beleodaq (belinostat) inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). | 23274910 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02679131 | Phase I | Belinostat | To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment. | Terminated | USA | 0 |
NCT06561048 | Phase III | Pralatrexate CPI-818 Belinostat | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Recruiting | USA | 0 |
NCT02532192 | Phase I | Rituximab Cisplatin Dexamethasone Cytarabine Fluconazole Belinostat | A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Withdrawn | 0 | |
NCT02701673 | Phase Ib/II | Azacitidine Pyridoxine Gemcitabine Belinostat Busulfan Melphalan | Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | Withdrawn | 0 | |
NCT03432741 | Phase I | Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | Suspended | USA | 0 |
NCT04184869 | Phase I | Belinostat Atazanavir + Belinostat | Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials | Completed | USA | 0 |
NCT04747236 | Phase II | Pralatrexate Belinostat Azacitidine + Romidepsin Gemcitabine Romidepsin | A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) | Recruiting | USA | 0 |
NCT02680795 | Phase I | Belinostat | To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes | Completed | USA | 0 |
NCT01273155 | Phase I | Belinostat | Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction | Completed | USA | 0 |
NCT01686165 | Phase II | Belinostat Rituximab | Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT02142530 | Phase I | Belinostat Carfilzomib | Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | Completed | USA | 0 |